

Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

October 3, 2018

NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Helmerich & Payne, Inc. (NYSE:HP), Buckeye Partners L.P. (NYSE:BPL), Covanta Holding Corporation (NYSE:CVA), Summit Midstream Partners, LP (NYSE:SMLP), and Seattle Genetics, Inc. (NASDAQ:SGEN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

RARE DOWNLOAD: <http://MarketSourceResearch.com/register/?so=RARE>

HP DOWNLOAD: <http://MarketSourceResearch.com/register/?so=HP>

BPL DOWNLOAD: <http://MarketSourceResearch.com/register/?so=BPL>

CVA DOWNLOAD: <http://MarketSourceResearch.com/register/?so=CVA>

SMLP DOWNLOAD: <http://MarketSourceResearch.com/register/?so=SMLP>

SGEN DOWNLOAD: <http://MarketSourceResearch.com/register/?so=SGEN>

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Helmerich & Payne, Inc. (NYSE:HP), Buckeye Partners L.P. (NYSE:BPL), Covanta Holding Corporation (NYSE:CVA), Summit Midstream Partners, LP (NYSE:SMLP), and Seattle Genetics, Inc. (NASDAQ:SGEN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

Important Notice: *the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 1st, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.*

ULTRAGENYX PHARMACEUTICAL INC. (RARE) REPORT OVERVIEW

Ultragenyx Pharmaceutical's Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ultragenyx Pharmaceutical reported revenue of \$2.61MM vs \$0.13MM (up 1,863.91%) and analysts estimated basic earnings per share -\$7.12 vs -\$6.21. Analysts expect earnings to be released on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -\$1.87. The estimated EPS forecast for the next fiscal year is -\$6.53 and is expected to report on February 19th, 2019.

To read the full Ultragenyx Pharmaceutical Inc. (RARE) report, download it here: <http://MarketSourceResearch.com/register/?so=RARE>

HELMERICH & PAYNE, INC. (HP) REPORT OVERVIEW

Helmerich & Payne's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Helmerich & Payne reported revenue of \$648.87MM vs \$498.56MM (up 30.15%) and analysts estimated basic earnings per share -\$0.08 vs -\$0.21. For the twelve months ended September 30th, 2017 vs September 30th, 2016, Helmerich & Payne reported revenue of \$1,804.74MM vs \$1,624.23MM (up 11.11%) and analysts estimated basic earnings per share -\$1.20 vs -\$0.54. Analysts expect earnings to be released on November 15th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -\$0.13. The estimated EPS forecast for the next fiscal year is \$0.99 and is expected to report on November 15th, 2018.

To read the full Helmerich & Payne, Inc. (HP) report, download it here: <http://MarketSourceResearch.com/register/?so=HP>

BUCKEYE PARTNERS L.P. (BPL) REPORT OVERVIEW

Buckeye Partners' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Buckeye Partners reported revenue of \$940.84MM vs \$810.20MM (up 16.12%) and analysts estimated basic earnings per share \$0.59 vs \$0.80 (down 26.25%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Buckeye Partners reported revenue of \$3,648.15MM vs \$3,248.38MM (up 12.31%) and analysts estimated basic earnings per share \$3.33 vs \$4.05 (down 17.78%). Analysts expect earnings to be released on November 2nd, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was \$0.81. The estimated EPS forecast for the next fiscal year is \$2.94 and is expected to report on February 8th, 2019.

To read the full Buckeye Partners L.P. (BPL) report, download it here: <http://MarketSourceResearch.com/register/?so=BPL>

COVANTA HOLDING CORPORATION (CVA) REPORT OVERVIEW

Covanta Holding's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Covanta Holding reported revenue of \$454.00MM vs \$424.00MM (up 7.08%) and basic earnings per share -\$0.24 vs -\$0.28. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Covanta Holding reported revenue of \$1,752.00MM vs \$1,699.00MM (up 3.12%) and analysts estimated basic earnings per share \$0.44 vs -\$0.03. Analysts expect earnings to be released on October 25th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was \$0.12. The estimated EPS forecast for the next fiscal year is \$0.07 and is expected to report on February 28th, 2019.

To read the full Covanta Holding Corporation (CVA) report, download it here: <http://MarketSourceResearch.com/register/?so=CVA>

SUMMIT MIDSTREAM PARTNERS, LP (SMLP) REPORT OVERVIEW

Summit Midstream Partners, LP's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Summit Midstream Partners, LP reported revenue of \$128.18MM vs \$101.79MM (up 25.93%) and analysts estimated basic earnings per share -\$0.79 vs \$0.12. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Summit Midstream Partners, LP reported revenue of \$488.74MM vs \$402.36MM (up 21.47%) and analysts estimated basic earnings per share \$0.99 vs -\$0.71. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was \$1.22. The estimated EPS forecast for the next fiscal year is \$1.17 and is expected to report on February 28th, 2019.

To read the full Summit Midstream Partners, LP (SMLP) report, download it here: <http://MarketSourceResearch.com/register/?so=SMLP>

SEATTLE GENETICS, INC. (SGEN) REPORT OVERVIEW

Seattle Genetics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Seattle Genetics reported revenue of \$170.17MM vs \$108.22MM (up 57.24%) and analysts estimated basic earnings per share \$0.48 vs -\$0.39. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Seattle Genetics reported revenue of \$482.25MM vs \$418.15MM (up 15.33%) and analysts estimated basic earnings per share -\$0.88 vs -\$1.00. Analysts expect earnings to be released on October 25th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -\$0.19. The estimated EPS forecast for the next fiscal year is -\$0.23 and is expected to report on February 5th, 2019.

To read the full Seattle Genetics, Inc. (SGEN) report, download it here: <http://MarketSourceResearch.com/register/?so=SGEN>

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Hugo Moreau, Media Department

Office: +1 (704) 343-6361

E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Source: Market Source Research